Efficacy Profile of Intracameral XXXX . The Often Forgotten Step.

@entity1 @entity2379 @entity1036 @entity1066 @entity3283 @entity413
PURPOSE: The objectives of this study were to assess visual and structural outcomes in @entity1036 after conventional treatment (topical and systemic antifungals) and intracameral @entity2379 (ICAMB), and to evaluate any complications. DESIGN: This was a prospective, nonrandomized, nonblinded interventional study. METHODS: This study was conducted on 104 eyes of 104 @entity1 with @entity3283 . @entity1 were categorized into 2 groups: group A, who received conventional topical and systemic antifungal medications, and group B, who received ICAMB in the dose of 5 to 10  g in 1 mL of 5% @entity413 . Response to treatment was evaluated. Results of the 2 groups were compared with appropriate statistical indices. RESULTS: The mean final visual acuity in @entity1 in group B receiving ICAMB was 1.22    0.31 logMAR units. The improvement in mean visual acuity was 1.40    0.2 logMAR units. In group A, mean visual outcome was 1.25    0.73 logMAR units. There was an improvement by 0.55    0.30 logMAR units. Healing with varying degrees of opacification occurred in a significant number of @entity1 (81.48%) treated with ICAMB as compared with conventional treatment (Z = 2.24, P < 0.05). Complications, such as sloughing, occurred in significantly fewer @entity1 treated with ICAMB as compared with conventional treatment (Z = 2.29, P < 0.05). CONCLUSIONS: In cases of keratomycosis where response to local and systemic antifungal treatment is not evident after 7 days, ICAMB can be safely administered to prevent the progression of @entity1066 and the development of complications.
